Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluorouracil + sodium phenylbutyrate + indomethacin + interferon gamma-1b
- Development stage
- Unknown
- Lead developer
- National Cancer Institute
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
This combination therapy is an experimental regimen developed and studied by the National Cancer Institute (NCI) for the treatment of advanced or Stage IV colorectal cancer. The regimen integrates cytotoxic chemotherapy, epigenetic modulation, and immunotherapy. Fluorouracil (5-FU) serves as the backbone, acting as an antimetabolite that inhibits thymidylate synthase to impair DNA synthesis. Sodium phenylbutyrate is included as a histone deacetylase (HDAC) inhibitor to promote cell differentiation and potentially reverse chemoresistance. Indomethacin, a nonsteroidal anti-inflammatory drug (NSAID), is utilized to inhibit cyclooxygenase (COX) enzymes, thereby reducing pro-inflammatory prostaglandins that can promote tumor growth and immune evasion. Recombinant human interferon-gamma (interferon gamma-1b) is added as an immunomodulatory cytokine to enhance the host's antitumor immune response and potentially sensitize tumor cells to the effects of the other agents. This multi-pronged approach was evaluated in Phase I/II clinical trials to determine the optimal dosing and safety profile in patients with metastatic disease.
- Other names
- 5-FU + Phenylbutyrate + Indomethacin + IFN-gammaFluorouracil + Phenylbutyrate + Indomethacin + Interferon-Gamma
02
Targets
TS (Thymidylate synthase)IFNGR1 (Interferon gamma receptor 1)HDAC (HDAC family)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on fluorouracil + sodium phenylbutyrate + indomethacin + interferon gamma-1b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluorouracil + sodium phenylbutyrate + indomethacin + interferon gamma-1b.